Oslo, 21st of March 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 21st of March 2025, the Company purchased a total of 27,543 shares at an average price of NOK 187.9479 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview: 

-----------------------------------------------------------------------------

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)		

Date: 17 mars 2025. Number of share: 1479.  Avg price: NOK 189.4561 per share
Date: 18 mars 2025. Number of share: 2564.  Avg price: NOK 187.0456 per share
Date: 19 mars 2025. Number of share: 3500.  Avg price: NOK 186.6269 per share
Date: 20 mars 2025. Number of share: 3000.  Avg price: NOK 186.8238 per share
Date: 21 mars 2025. Number of share: 3000.  Avg price: NOK 185.6533 per share


Total for this period:
13,543 shares purchased at average share price of NOK 186.8430 per share. Total transaction value was NOK 2,530,415.94.


Previously disclosed buybacks under the program:
14,000 shares purchased at average share price of NOK 189.0167 per share. Total transaction value was NOK 2,646,234.75

-----------------------------------------------------------------------------

The issuer’s holding of own shares: 
Following the completion of the above transactions, Medistim owns a total of 50,660 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.276 % of Medistim’s share capital. 

Appendix: 
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact: 

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
